Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting

Autor: Agata Maria Rabuazzo, Roberto Scicali, Francesco Purrello, Antonino Di Pino, Salvatore Piro, Viviana Ferrara
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Endocrinology
Diabetes and Metabolism
Familial hypercholesterolemia
030204 cardiovascular system & hematology
Monocytes
Cohort Studies
Leukocyte Count
0302 clinical medicine
Endocrinology
030212 general & internal medicine
Prospective Studies
Pulse wave velocity
Innate immunity
Anticholesteremic Agents
PCSK9 Inhibitors
General Medicine
Middle Aged
Inflammatory profile
Italy
Cohort
Absolute neutrophil count
Cardiology
lipids (amino acids
peptides
and proteins)
Original Article
Drug Therapy
Combination
Female
Blood Flow Velocity
medicine.drug
medicine.medical_specialty
Pulse Wave Analysis
Hyperlipoproteinemia Type II
03 medical and health sciences
Ezetimibe
Internal medicine
Diabetes mellitus
Internal Medicine
medicine
Humans
Aged
business.industry
PCSK9
Cholesterol
HDL
medicine.disease
Cardiovascular risk
Lipid Metabolism
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Lipoprotein
Zdroj: Acta Diabetologica
ISSN: 1432-5233
0940-5429
Popis: Aims Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. Methods In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. Results After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (− 49.61%, p p value for both p p p value for both Conclusions In conclusion, PCSK9-i therapy significantly improved lipid and inflammatory profiles and PWV values in FH subjects; our results support the positive effect of PCSK9-i in clinical practice.
Databáze: OpenAIRE
Externí odkaz: